share_log

Hypera (OTCMKTS:HYPMY) Share Price Passes Above 50-Day Moving Average of $7.58

Defense World ·  Aug 5, 2022 03:51

Shares of Hypera S.A. (OTCMKTS:HYPMY – Get Rating) passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $7.58 and traded as high as $8.14. Hypera shares last traded at $8.12, with a volume of 2,876 shares traded.

Hypera Stock Performance

The business's 50-day simple moving average is $7.58 and its 200-day simple moving average is $7.23. The company has a market capitalization of $5.14 billion, a price-to-earnings ratio of 19.17 and a beta of 0.82.

Hypera Company Profile

(Get Rating)

Hypera SA operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands.

Recommended Stories

  • Get a free copy of the StockNews.com research report on Hypera (HYPMY)
  • Can FuelCell Energy Surge Higher This Year?
  • Is It Time to Take a Ride on Cedar Fair Stock?
  • These Are The Top Insider Buying Stocks For July
  • Time To Take A Serious Look At Nikola Stock As Production Starts
  • Chipotle Mexican Grill Or Shake Shak? Which Is The Tastier Play

Receive News & Ratings for Hypera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hypera and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment